Protecting humanity against some of the world’s more severe infectious diseases
A LEADER IN GLOBAL HEALTH & INFECTIOUS DISEASES
WHO WE ARE
SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs.
Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.
Society must take proactive steps to prevent and stop outbreaks – whether natural, accidental, or intentional. We are committed to partnering with governments, commercial organizations, foundations, and others who share responsibility for global health security.
HOW WE DO IT
Our experienced, multidisciplinary team has a profound passion for innovation and public health advancement.
As orthopoxvirus threats loom, our team is steadfast in its goal of ensuring governments and other key stakeholders are equipped with medicines and other countermeasures to combat devastating diseases. By preparing for the unthinkable, we help build a resilient defense against devastating outbreaks. We are committed to safeguarding your health which preserves your peace of mind through our collective proactive and unwavering efforts.
COMPANY
SIGA by the Numbers
30+
Countries in which
Products are Sold
50
Employees
>$1B
10 years of Global
Government Partnerships
$139M
2024 Global Revenues
COLLABORATION PARTNERS
Our Industry Partners
We are equipped to respond rapidly to orthopoxvirus outbreaks, collaborating with healthcare professionals, governments, and communities to minimize the spread and impact on people.
Global cooperation is essential to prevent and stop infectious disease outbreaks. Our rich history of successful partnerships with over 25 countries and many organizations enables an extensive reach across multiple stakeholders to combat orthopoxvirus outbreaks. Additionally, the U.S. government has relied on our TPOXX treatment for over a decade to equip the Strategic National Stockpile (SNS) against a potential smallpox outbreak.
OUR PRODUCT
TPOXX® (tecovirimat) is a best-in-class product franchise
TPOXX is a highly targeted antiviral with a strong safety profile. It prevents viral particles from exiting the cell in which they are produced, thereby slowing the spread of infection, and allowing the patient’s immune system to clear the virus.
Oral TPOXX was the first U.S. FDA-approved antiviral treatment for smallpox. It is also available in the U.S. in an IV formulation. In Canada, oral TPOXX is approved for the same indication. In the EU and UK, TPOXX, under the brand name Tecovirimat-SIGA, and in Japan, under the brand name TEPOXX, is approved for the treatment of orthopoxvirus infections, including mpox, smallpox, cowpox, and vaccinia complications following vaccination against smallpox.
Additionally, we are working to advance regulatory approval for TPOXX in new indications and formulations, including as a post-exposure prophylaxis (PEP) for smallpox, treatment for mpox (U.S.), and a pediatric formulation for the treatment of smallpox.
Protecting humanity against some of the world’s more severe infectious diseases to give you peace of mind